North America Multiomics Market (2026-2031)
The North America Multiomics Market was valued at $1409 Million in 2026 and projected to reach to $2546.4 Million by 2031, representing a compound annual growth rate of 12.6%. North America's multiomics market is positioned for sustained expansion through 2031, driven by increasing adoption of integrated genomic, proteomic, and metabolomic approaches in clinical diagnostics and drug development.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America Multiomics Market Trends and Insights
- This accelerated growth in North America outpaces the global average, driven by advanced healthcare infrastructure, significant R&D investments, and widespread adoption of precision medicine across the region.
- North America's leadership in genomic sequencing, proteomics, and metabolomics technologies positions it as a critical hub for multiomics innovation and commercialization. The North America multiomics market benefits from strong regulatory frameworks, established reimbursement pathways, and a concentration of leading biotechnology and pharmaceutical companies.
- North America's healthcare systems increasingly integrate multiomics data into clinical diagnostics and drug development pipelines, accelerating market penetration.
- Between 2026 and 2031, North America is expected to capture substantial market share as healthcare providers and research institutions expand multiomics capabilities to improve patient outcomes and reduce healthcare costs..
Key Market Statistics
- CAGR (2026-2031) 12.6% CAGR
- Market Size, 2026 ~USD 1409 Million
- Forecast, 2031 ~USD 2546.4 Million
- Geography North America
North America Multiomics Market Overview
Market Leadership Position :
North America commands the largest share of the global multiomics market, valued at $1,409.0 million in 2026 with projected growth to $2,546.4 million by 2031, demonstrating regional dominance in precision medicine adoption.
Above-Average Growth Trajectory :
North America's 12.6% CAGR outpaces the global average of 12.3%, driven by robust healthcare infrastructure, substantial pharmaceutical R&D investments, and accelerating precision medicine implementation across major medical centers.
US Market Dominance :
The United States represents the largest market within North America at $1,874.2 million, reflecting advanced biotechnology capabilities, FDA regulatory support for multiomics applications, and high healthcare spending on innovative diagnostics.
Strategic Investment Hub :
North America attracts significant venture capital and corporate funding for multiomics startups and research initiatives, supported by leading academic institutions and biotech clusters in California, Massachusetts, and other innovation hubs.
North America Multiomics Market Dynamics
- Healthcare providers across the region are investing heavily in multiomics platforms to enable personalized treatment strategies and improve patient outcomes.
- The region benefits from strong regulatory frameworks, substantial healthcare budgets, and a concentration of leading pharmaceutical and diagnostic companies. Key growth catalysts include rising prevalence of chronic diseases, growing demand for companion diagnostics, and expanding applications in oncology and rare disease identification.
- North American healthcare systems are increasingly recognizing multiomics as essential for precision medicine implementation, with major hospital networks and research institutions integrating these technologies into clinical workflows.
- Continued innovation in data analytics and bioinformatics tools will further accelerate market penetration through 2031..
Market Ecosystem
MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. | Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina) |
 |
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. | Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- North America's multiomics market will nearly double from $1,409.0M (2026) to $2,546.4M (2031) at a 12.6% CAGR.
- North America leads global multiomics adoption due to advanced infrastructure, regulatory support, and precision medicine integration.
- Strong R&D investment and reimbursement pathways in North America accelerate clinical and commercial multiomics deployment.
- North America's concentration of biotech firms and healthcare systems drives innovation and market consolidation through 2031.
Multiomics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 12.3% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 3.19 (2026) |
| Revenue Forecast (Billions) | ~USD 5.7 (2031) |
| Segments Covered | Offering, Type, Technology, Method, Workflow, Application, End User |
North America Multiomics Market Report Segmentation
7 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Assay Kits & Reagents
- Consumables
- Instruments & Software
- Long-Read Sequencing
- Ms-Based Proteomics
- Nanopore Sequencing
- Ngs-Based Proteomics
- Other Consumables
- Other Proteomics Methods
- Other Sequencing Technologies
- Pcr-Based Proteomics
- Smrt Sequencing
By Technology
- Long-Read Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Other Technologies
- Proteomics
- Sequencing
- Smrt Sequencing
By Method
- Chromatin Accessibility Sequencing
- Chromatin Interaction Analysis
- Dna Methylation Sequencing
- Epigenomics
- Histone Modification Profiling
- Long-Range Sequencing
- Long-Read & Long-Range Sequencing
- Long-Read Sequencing
- Ms-Based Proteomics
- Ngs-Based Proteomics
- Other Epigenomics Methods
- Other Long-Read & Long-Range Sequencing Methods
- Other Methods
- Other Proteomics Methods
- Other Single-Cell Omics
- Other Spatial Omics
- Pcr-Based Proteomics
- Proteomics
- Sequencing-Based Epigenomics
- Single-Cell Epigenomics
- Single-Cell Genomics
- Single-Cell Omics
- Single-Cell Proteomics
- Single-Cell Transcriptomics
- Spatial Epigenomics
- Spatial Genomics
- Spatial Omics
- Spatial Proteomics
- Spatial Transcriptomics
By Workflow
- Data Visualization & Analysis
- Sample Preparation
- Sequencing & Analysis/ Sample Characterization
- Sequencing & Analysis/Sample Characterization
By Application
- Biomarker Discovery
- Cell Biology
- Clinical Diagnostics
- Drug Discovery & Development
- Immunology
- Neurology
- Oncology
- Other Applications
- Precision Medicine
- Translational Research
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Hospitals & Diagnostic/Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
Target Audience
- Pharmaceutical & Biotech Companies : Develop multiomics-based drug discovery and companion diagnostic strategies aligned with North American market demand, regulatory pathways, and healthcare provider adoption trends to maximize ROI on precision medicine investments.
- Diagnostic & Laboratory Service Providers : Expand multiomics testing portfolios and clinical laboratory capabilities by understanding North American market growth opportunities, reimbursement models, and hospital/clinic integration requirements for precision diagnostics.
- Healthcare Systems & Hospital Networks : Evaluate multiomics technology adoption for precision oncology, rare disease diagnosis, and personalized treatment planning by analyzing North American market trends, vendor landscapes, and clinical implementation best practices.
- Investment & Venture Capital Firms : Identify high-potential multiomics startups and investment opportunities within North America's thriving biotech ecosystem by analyzing market growth projections, competitive dynamics, and emerging technology trends through 2031.
- Healthcare Policy & Regulatory Bodies : Inform reimbursement policies, clinical guidelines, and regulatory frameworks for multiomics applications by understanding North American market adoption rates, healthcare provider needs, and precision medicine implementation challenges.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 1874.2 Million |
| Canada | USD 194.4 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Access detailed market valuations for North America ($1,409M in 2026) and country-level breakdowns for US and Canada, enabling precise budget allocation and market entry strategies specific to this high-growth region.
- Competitive Landscape Intelligence : Understand the competitive positioning of multiomics providers within North America's advanced healthcare ecosystem, identifying market leaders, emerging players, and partnership opportunities in precision medicine.
- Growth Driver Analysis : Identify region-specific growth catalysts including FDA regulatory trends, healthcare infrastructure investments, R&D spending patterns, and adoption rates of precision medicine across North American healthcare systems.
- Investment & Expansion Guidance : Make informed decisions on market entry, product launches, and partnership strategies tailored to North America's regulatory environment, reimbursement landscape, and healthcare provider preferences.
- Trend Forecasting Through 2031 : Leverage 12.6% CAGR projections and market evolution insights to anticipate future demand, technology adoption patterns, and emerging applications in oncology, rare diseases, and personalized medicine across North America.
Frequently asked questions
What is the projected size of North America's multiomics market in 2031?
North America's multiomics market is projected to reach $2,546.4 million by 2031, growing from $1,409.0 million in 2026.
What is the CAGR for North America's multiomics market?
North America's multiomics market is expected to grow at a compound annual growth rate of 12.6% between 2026 and 2031.
Why is North America's multiomics market growing faster than the global average?
North America benefits from advanced healthcare infrastructure, robust regulatory frameworks, significant R&D investments, and widespread precision medicine adoption, supporting accelerated multiomics market expansion.
Which sectors are driving North America's multiomics market growth?
North America's multiomics growth is driven by pharmaceutical R&D, clinical diagnostics, precision medicine initiatives, and biotechnology innovation across healthcare systems and research institutions.
How does North America's multiomics market compare to other regions?
North America's 12.6% CAGR exceeds the global average of 12.3%, reflecting the region's leadership in multiomics technology adoption and commercialization.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Multiomics Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.
Key Stakeholders
- Multiomics product & service providers
- Multiomics bioinformatics/data analysis companies
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Hospitals and diagnostic clinics
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe multiomics market, by country
- Further breakdown of the Rest of Asia Pacific multiomics market, by country
Company Analysis
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Multiomics Market Report
Full forecast, segment splits, and company analysis for all Multiomics Market.
- Canada Multiomics Market
- US Multiomics Market
- Germany Multiomics Market
- UK Multiomics Market
- France Multiomics Market
- Italy Multiomics Market
- Spain Multiomics Market
- China Multiomics Market
- Japan Multiomics Market
- South Korea Multiomics Market
- India Multiomics Market
- Australia Multiomics Market
- Brazil Multiomics Market
- Saudi Arabia Multiomics Market
- UAE Multiomics Market
- Rest Of Europe Multiomics Market
- Rest Of Asia Pacific Multiomics Market
- Rest Of Latin America Multiomics Market
- Rest Of GCC Countries Multiomics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
